Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population
Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population
复制标题
DOI：
10.1007/s12032-014-0935-2
复制
发表时间：
2014-05-01
期刊：
影响因子：
3.4
通讯作者：
Qiu, Meng
中科院分区：
文献类型：
--
作者：
Chen, Ye;Cao, Dan;Qiu, Meng
每周一次的西妥昔单抗联合伊立替康方案是KRAS野生型转移性结直肠癌（mCRC）患者的标准一线和二线化疗。然而，化疗方案每2周给药一次，与西妥昔单抗每周给药不同步。本研究探讨了西妥昔单抗每两周给药一次在mCRC患者中的疗效和安全性。回顾性分析2010年5月至2013年2月在华西医院接受西妥昔单抗双周联合FOLFIRI/伊立替康一线/二线化疗、至少3个周期西妥昔单抗治疗和1次CT评估的26例KRAS野生型mCRC患者。西妥昔单抗给药的中位次数为8.3（范围3-20）。14例患者接受FOLFIRI作为一线治疗;缓解率为50.0%;中位PFS为8.8个月（95% CI 4.9-12.7）。10例患者接受FOLFIRI治疗，2例患者接受伊立替康作为二线治疗;缓解率为33.3%;中位PFS为4.6个月（95% CI 0.9-8.3）。毒性与每周一次西妥昔单抗联合给药方案相似。在69.2%的可评价患者中观察到皮疹（7.7%为3级）。总体而言，我们的研究结果表明，西妥昔单抗联合FOLFIRI/伊立替康每两周一次治疗与标准每周一次治疗一样有效和安全。
Weekly cetuximab plus irinotecan-based regiments are standard first-and second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC). However, the chemotherapy regimens are given every 2 weeks, which is asynchronous with cetuximab weekly administration. This study investigated the efficacy and safety of biweekly cetuximab administration in patients with mCRC. Twenty-six patients with KRAS wild-type mCRC, who received biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy, at least three cycles of cetuximab and once CT evaluation in West China Hospital from May 2010 to February 2013, were retrospectively analyzed. The median number of cetuximab administrations was 8.3 (range 3-20). Fourteen patients received FOLFIRI as first-line therapy; response rate was 50.0 %; median PFS was 8.8 months (95 % CI 4.9-12.7). Ten patients received FOLFIRI and two patients received irinotecan as second-line therapy; response rate was 33.3 %; median PFS was 4.6 months (95 % CI 0.9-8.3). The toxicity was similar to weekly cetuximab combination schedules. Rash was observed in 69.2 % of evaluable patients (grade 3 in 7.7 %). Overall, our results show that biweekly cetuximab plus FOLFIRI/irinotecan may be as effective and safe as the standard weekly schedule.